Navigation Links
AtheroNova Initiates Phase 1 Clinical Trial of AHRO-001, a Potential Treatment for Atherosclerosis
Date:6/25/2013

IRVINE, Calif., June 25, 2013 /PRNewswire/ -- AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the initiation of a Phase 1 clinical trial with its lead compound, AHRO-001.  The Phase 1 study will evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers. The clinical study is being conducted in Russia with AtheroNova's licensing partner, OOO CardioNova.

"There is a significant unmet need for effective and well-tolerated agents in the treatment of both atherosclerosis and lipid modulation," said Thomas W. Gardner, Chairman and Chief Executive Officer of AtheroNova.  "Based on AHRO-001's preclinical profile, we believe it has the potential to offer patients effective treatment for these chronic conditions with an improved therapeutic profile.  We look forward to assessing AHRO-001 in human trials and are extremely pleased to have met a significant milestone with transitioning into a clinical stage company."

The Phase 1 study is a randomized, double-blind, placebo controlled study that assesses ascending doses of AHRO-001 in healthy adult volunteers.  The program advanced into Phase 1 clinical testing following extensive successful preclinical studies with AHRO-001.

"This is clearly an exciting and transformative time for us," remarked Mark K. Wedel, MD, Chief Medical Officer of AtheroNova.

About AHRO-001

AHRO-001 is AtheroNova's first novel application for the treatment and prevention of atherosclerosis. Atherosclerotic plaque is the primary, underlying cause of heart disease and stroke in industrialized countries. AtheroNova has shown positive results in animal models for regression of pl
'/>"/>

SOURCE AtheroNova Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. AtheroNova Announces Milestone Filing of IND in Russian Federation
2. AtheroNova Receives Notice of Allowance for Its US Patent Application 12/024,908
3. AtheroNova Signs Agreement for Development of Clinical Trial Supplies
4. Xenon Licenses Antisense Drug XEN701 From Isis and Initiates Preclinical Toxicology Studies
5. Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients
6. AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy
7. Soligenix Initiates Phase 1 Clinical Study with SGX203 for the Treatment of Pediatric Crohns Disease
8. Ambrx Initiates Collaboration with Bristol-Myers Squibb for Discovery, Development of Next-Generation Antibody Drug Conjugates
9. Acutus Medical, Inc. Initiates "First-In-Man" Clinical Study of Real-Time 3D Imaging Catheter with CT/MRI Quality
10. ISIS Pharmaceuticals Initiates a Clinical Study of ISIS-SMN Rx in Infants With Spinal Muscular Atrophy
11. Romark Laboratories Initiates Phase 3 Trial of New Influenza Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... -- Emerus Holdings, a national and innovative leader ... care in partnership with leading health systems, today ... receive a strategic investment from Welsh, Carson, Anderson ... investment firm. Emerus partners with health ... ambulatory clinical services to communities across a given ...
(Date:9/1/2015)... IRVINE, Calif. , Sept. 1, 2015  Edwards ... in the science of heart valves and hemodynamic monitoring, ... Fargo Healthcare Conference at the Hyatt Regency Boston in ... 9, 2015. Michael A. Mussallem , ... keynote lunch speaker followed by a company discussion with ...
(Date:9/1/2015)... -- Taiwan,s GNT Biotech & ... Taipei on  August 25 th ... targeted drug delivery technology that uses nano-scale gold as ... of a joint press conference held by its parent ... GNT,s latest edible gold-based food and beverage partners, together ...
Breaking Medicine Technology:Emerus Announces Significant Strategic Investment By Welsh, Carson, Anderson & Stowe 2Emerus Announces Significant Strategic Investment By Welsh, Carson, Anderson & Stowe 3GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 2GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 3GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 4GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 5
... 2011 Reportlinker.com announces that a new market ... US Wound Closure Devices – Market ... Short Description ... on the wound closure devices in US. It ...
... DecisionView Inc., a leading provider of software ... sciences companies, today announced that a number of ... agreed to participate in the creation of a ... real-world clinical performance data. Each of the initial ...
Cached Medicine Technology:Reportlinker Adds US Wound Closure Devices - Market Trend Till 2016 2DecisionView to Create Clinical Trial Enrollment Benchmarks 2DecisionView to Create Clinical Trial Enrollment Benchmarks 3
(Date:9/2/2015)... ... September 02, 2015 , ... Canopy Partners, a ... to the Inc. 5000 List, an independent ranking of the fastest- growing ... years, and this achievement puts Canopy in rarefied company. Over the years, this ...
(Date:9/2/2015)... ... September 02, 2015 , ... Traveling to the Caribbean can be ... magnificent flora and fauna. , Lifestyle Holidays Vacation Club knows that ... make travelers experience that much better, Lifestyle Holidays Vacation Club has put together its ...
(Date:9/1/2015)... ... September 01, 2015 , ... September is National Prostate Cancer ... affects more than 233,000 men each year in the United States. , Prostate cancer ... non-skin cancer in America, affecting 1 in 7 men. One new case occurs every ...
(Date:9/1/2015)... ... 2015 , ... Earth Brands, ( http://www.earthbrands.com ) a comfort-meets-fashion ... who buys an Earth Brand shoe will be given an opportunity to plant ... Future, a nonprofit dedicated to planting more trees. Earth Brands products represent contemporary ...
(Date:9/1/2015)... ... September 01, 2015 , ... Stress comes ... created from everyday life changes can lead to very serious, life-altering events. Fortunately ... coping with stress. Herbal supplement manufacturer MediHerb has coupled therapeutic doses ...
Breaking Medicine News(10 mins):Health News:Canopy Partners Named to 2015 Inc. 5000 Fastest Growing Companies List 2Health News:Lifestyle Holidays Vacation Club Lists 3 Things to Consider When On a Puerto Plata Vacation 2Health News:Lifestyle Holidays Vacation Club Lists 3 Things to Consider When On a Puerto Plata Vacation 3Health News:September is Prostate Cancer Awareness Month 2Health News:September is Prostate Cancer Awareness Month 3Health News:Earth Brands Footwear Partners with Trees for the Future for Launch of Fall Collection: Buy Shoes, Plant a Tree 2Health News:Earth Brands Footwear Partners with Trees for the Future for Launch of Fall Collection: Buy Shoes, Plant a Tree 3Health News:MediHerb Launches New Herbal Supplement to Help with the Challenges of Everyday Life 2Health News:MediHerb Launches New Herbal Supplement to Help with the Challenges of Everyday Life 3
... say finding suggests alternate vision routes in the brain , , ... of second sight: Scientists report that a blind man in ... even though he has no conscious sensation of seeing the ... that the human brain has ways of processing vision beyond ...
... patients with autoimmune diseases like lupus and rheumatoid arthritis ... too, according to a new report in the ... these cells are maintained in an ,off, state, perhaps ... true predecessors of the self-attacking cells prevalent in lupus ...
... woes ratchet up mental health problems already more common this ... --Sagging spirits, sagging economy. , That,s the holidays this ... -- the usual melancholy compounded by the highest jobless rate ... "Mental health problems are common and spike more often during ...
... Eve , ... Terre Haute, Ind. (PRWEB) December 22, 2008 -- Fleschner, Stark, Tanoos ... provide free transportation to those who can,t drive or feel they don,t have ... Cab Ride Home program will be available from 10 p.m. on Wednesday, December ...
... two proteins which work in tandem in the brain,s blood ... do the proteins lessen blood flow in the brain, but ... able to remove amyloid beta, the protein that builds up ... disease. , The work, described in a paper published online ...
... pressures can be overcome with honest approach to food, ... The holiday season can be especially difficult for overweight ... eating habits and cope with widely held misconceptions, according ... people feel self-conscious about what they wear and what ...
Cached Medicine News:Health News:'Blind' Man Navigates Obstacle Course Without Error 2Health News:Potential autoimmunity-inducing cells found in healthy adults 2Health News:Blue and Broke for the Holidays 2Health News:Blue and Broke for the Holidays 3Health News:Blue and Broke for the Holidays 4Health News:Fleschner, Stark, Tanoos & Newlin to Offer Free Terre Haute Cab Rides on New Year's Eve 2Health News:Fleschner, Stark, Tanoos & Newlin to Offer Free Terre Haute Cab Rides on New Year's Eve 3Health News:Two cardiovascular proteins pose a double whammy in Alzheimer's 2Health News:Two cardiovascular proteins pose a double whammy in Alzheimer's 3Health News:Two cardiovascular proteins pose a double whammy in Alzheimer's 4Health News:For the Obese, Holiday Tables Serve Platefuls of Doubt 2
The removable inflation/injection adapter allows the cystoscope to be removed after the catheter is in place. Supplied sterile in peel-open packages. Intended for one-time use....
Gold radiopaque markers indicate the proximal and distal ends of the balloon. Supplied sterile in peel-open packages. Intended for one-time use....
... The tipless balloon design allows the ureter ... A radiopaque marker at the base of ... extent of ureteral dilation. Supplied sterile in ... includes:, Pin Vise Handle (plastic), Straight Safety ...
Used retrograde to dilate the ureter and establish a conduit for a flexible ureteroscope. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: